Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | CCR6 | P51684 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 7/20 | 0.84 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.83 |
| ▸ | CASP1 | P29466 | 1/20 | 0.83 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | TP53 | P04637 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 1/20 | 0.83 |
| ▸ | HPGD | P15428 | 1/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.83 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.83 |
| ▸ | TERT | O14746 | 7/20 | 0.82 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Celastrol SCHEMBL17130559 | 1.00 | HSP90AA1 (1.00) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| Celastrol SCHEMBL14954 | 1.00 | HSP90AA1 (1.00) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| Celastrol SCHEMBL25510440 | 1.00 | HSP90AA1 (1.00) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| Celastrol SCHEMBL15813281 | 1.00 | HSP90AA1 (1.00) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| Celastrol SCHEMBL19745423 | 1.00 | HSP90AA1 (1.00) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| Celastrol SCHEMBL17430781 | 1.00 | HSP90AA1 (1.00) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| Celastrol SCHEMBL20547678 | 0.99 | HSP90AA1 (0.98) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| SCHEMBL12395103 | 0.93 | HSP90AA1 (0.86) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| SCHEMBL13287257 | 0.92 | HSP90AA1 (0.86) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| Celastrol SCHEMBL23777521 | 0.92 | HSP90AA1 (0.84) | HSP90AA1CCR6PAX8TLR9NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| WO-2023086467-A1 | CELASTROL PROTEOLYSIS TARGETING CHIMERAS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11446312-B2 | Compounds that modulate von Willebrand factor levels and their use in the treatment of blood disorders | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2022-09-20 | — | — | US | disclosed |
| US-10688105-B2 | Method of treating refractory rheumatoid arthritis associated with p53 mutation | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2020-06-23 | — | — | US | disclosed |
| US-10322097-B2 | Treatment of subjects with multidrug-resistant cancer | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2019-06-18 | — | — | US | disclosed |
| US-20170128394-A1 | TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-05-11 | — | — | US | disclosed |
| US-20170128394-A1 | TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128394-A1 | TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER | TP53, ABCB1, ABCC1 | HSP90AA1 546/4885CCR6 2686/4885PAX8 3565/4885 |
| US-11446312-B2 | Compounds that modulate von Willebrand factor levels and their use in the treatment of blood disorders | F5, F2, F3 | HSP90AA1 757/4885CCR6 2721/4885PAX8 3643/4885 |
| US-10322097-B2 | Treatment of subjects with multidrug-resistant cancer | TP53, ABCB1, ABCC1 | HSP90AA1 546/4885CCR6 2686/4885PAX8 3565/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | HSP90AA1 2110/4885CCR6 1615/4885PAX8 4249/4885 |
| US-10688105-B2 | Method of treating refractory rheumatoid arthritis associated with p53 mutation | TP53, SQSTM1, TP53BP1 | HSP90AA1 353/4885CCR6 3963/4885PAX8 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.